Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24259291 | 0.85 | NR1H4 (0.46) | NR1H4SUCNR1 | |
| SCHEMBL24259503 | 0.79 | NR1H4 (0.43) | NR1H4LTB4R2SUCNR1 | |
| SCHEMBL24258829 | 0.74 | NR1H4 (0.41) | NR1H4PLCG1POLQ | |
| SCHEMBL24259277 | 0.73 | NR1H4 (0.40) | NR1H4PLCG1 | |
| SCHEMBL24259134 | 0.71 | NR1H4 (0.50) | NR1H4 | |
| SCHEMBL24259043 | 0.70 | NR1H4 (0.38) | NR1H4PLCG1 | |
| SCHEMBL24258731 | 0.70 | FAAH (0.37) | NR1H4LTB4R2SUCNR1 | |
| SCHEMBL24259321 | 0.69 | NR1H4 (0.41) | NR1H4 | |
| SCHEMBL24258768 | 0.66 | CRY1 (0.32) | — | |
| SCHEMBL24259053 | 0.65 | CNR1 (0.42) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885PLCG1 1826/4885LTB4R2 216/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885PLCG1 1826/4885LTB4R2 216/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885PLCG1 1826/4885LTB4R2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.